Corcept Therapeutics (NASDAQ: CORT) has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE